Biotech News

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia (NTLA)Intellia2026-09-04 20:05 ESTCompany update

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement

Related news

NTLAIntellia2026-09-08 12:00 EST

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

NTLAIntellia2026-06-01 11:30 EST

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

ABEOAbeona Therapeutics2026-09-01 11:30 EST

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPTSarepta Therapeutics2026-07-29 21:00 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MXCTMaxCyte2026-09-11 20:30 EST

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TSHATaysha Gene Therapies2026-09-04 12:00 EST

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MGTXMeiraGTx2026-08-06 20:30 EST

MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

EDITEditas Medicine2026-09-09 13:00 EST

Editas Medicine Reports Inducement Grants to New Chief Medical Officer

ABEOAbeona Therapeutics2026-09-16 11:30 EST

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

SRPTSarepta Therapeutics2026-09-08 13:00 EST

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year

View all latest news

Intellia

In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed...

Recent company news

NTLAIntellia2026-09-08 12:00 EST

Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)

NTLAIntellia2026-09-04 20:05 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NTLAIntellia2026-09-04 12:50 EST

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

NTLAIntellia2026-09-04 12:00 EST

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

NTLAIntellia2026-08-07 20:01 EST

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close: 12.26 USD
Market cap: 1.83B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States